Spiro Medical

Spiro Medical is a private, clinical-stage medical device company pioneering neuromodulation for chronic respiratory diseases. The company's core technology, the Spiro Neuromodulation System, aims to treat severe asthma, chronic cough, and COPD by modulating airway nerves, offering a potential alternative to drug-based therapies. Operating in the large and growing respiratory therapeutics market, Spiro Medical is positioned to address significant unmet needs in patient populations poorly served by current standards of care. As a pre-revenue entity, its success hinges on clinical validation, regulatory clearance, and subsequent commercial execution of its lead device.

Implantable or minimally invasive neuromodulation system designed to treat chronic airway diseases by electrically modulating relevant neural pathways.

Spiro Medical competes indirectly with pharmaceutical companies marketing biologics (e.g., for severe asthma) and chronic cough therapies. Direct competitors may include other companies exploring airway neuromodulation, though the field is nascent. Broader competition includes all standard-of-care inhalers and systemic medications for asthma and COPD.